Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  China Biologic Products Holdings, Inc.    CBPO   KYG215151047

CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.

(CBPO)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

China Biologic Products : receives offer to be taken private at $120 a share

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/18/2019 | 11:21pm EDT

(Reuters) - China Biologic Products Holdings Inc said on Wednesday it had received an offer from a consortium of buyers that will pay $1.93 billion in cash to buy shares that they do not already own to take the company private.

Shares of the company, which develops plasma-based therapies and was listed on the Nasdaq in 2009, were up 7% after market.

The offer of $120 per share represents a premium of 16.3% to China Biologic's Wednesday close of $103.10, valuing the company at $4.59 billion.

The buyer group includes Beachhead Holdings Ltd, CITIC Capital China Partners IV LP, PW Medtech Group Ltd, Parfield Intern
ational Ltd, HH Sum-XXII Holdings Ltd and V-Sciences Investments Pte Ltd. (https://reut.rs/2mnFvlQ)

These companies in aggregate already beneficially own 58% of the total issued and outstanding share capital of the company, it said.

In August 2018, China Biologic rejected a $3.9 b
illion offer from a consortium led by its former chief executive officer. (https://reut.rs/2BKMZXo)

(Reporting by Bharath Manjesh in Bengaluru; Editing by Shounak Dasgupta and Stephen Coates)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CHINA BIOLOGIC PRODUCTS HO
09/24CHINA BIOLOGIC PRODUCTS : Forms Special Committee to Review "Going Private" Prop..
PR
09/18CHINA BIOLOGIC PRODUCTS : receives offer to be taken private at $120 a share
RE
08/05CHINA BIOLOGIC PRODUCTS : Reports Financial Results for the Second Quarter of 20..
PR
07/26CHINA BIOLOGIC PRODUCTS : to Report Second Quarter 2019 Financial Results
PR
07/03China's Centurium Capital raises over $2 billion from GIC, Temasek, others
RE
07/03China's Centurium Capital raises over $2 billion from GIC, Temasek, others
RE
05/10CHINA BIOLOGIC PRODUCTS : Reports Financial Results for the First Quarter of 201..
PR
04/30CHINA BIOLOGIC PRODUCTS : to Report First Quarter 2019 Financial Results
PR
03/06CHINA BIOLOGIC PRODUCTS : Reports Financial Results for the Fourth Quarter and F..
PR
02/25CHINA BIOLOGIC PRODUCTS : to Report Fourth Quarter and Fiscal Year 2018 Financia..
PR
More news
Financials (USD)
Sales 2019 502 M
EBIT 2019 160 M
Net income 2019 146 M
Finance 2019 937 M
Yield 2019 -
P/E ratio 2019 28,9x
P/E ratio 2020 26,8x
EV / Sales2019 6,91x
EV / Sales2020 6,78x
Capitalization 4 407 M
Chart CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
Duration : Period :
China Biologic Products Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHINA BIOLOGIC PRODUCTS HO
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Average target price 85,50  $
Last Close Price 115,18  $
Spread / Highest target -21,9%
Spread / Average Target -25,8%
Spread / Lowest Target -35,8%
EPS Revisions
Managers
NameTitle
Joseph Chow Chairman & Chief Executive Officer
Ming Yang Chief Financial Officer
Sean Shao Independent Director
Yun Gang Lu Independent Director
Hui Li Director
Sector and Competitors
1st jan.Capitalization (M$)
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.51.73%4 407
GILEAD SCIENCES2.30%81 040
VERTEX PHARMACEUTICALS2.72%44 315
REGENERON PHARMACEUTICALS-19.47%32 911
WUXI APPTEC CO., LTD.65.75%20 242
GENMAB23.89%12 836